[1] KEENAN C,NICHOLS K E,ALBEITUNI S.Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis[J].Front Immunol,2021,12:614704.
[2] RAMOS-CASALS M,BRITO-ZERÓN P,LÓPEZ-GUILLERMO A,et al.Adult haemophagocytic syndrome[J].Lancet,2014,383(9927):1503-1516.
[3] 王亚茹,贺建霞,耿晔,等.EB病毒相关噬血细胞综合征的临床特征及预后分析[J].现代肿瘤医学,2023,31(20):3840-3843.
[4] ZHOU D,HUANG X B,XIE M X,et al.Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis:a single-center pilot trial[J].American J Hematol,2023,98(5): E106-E109.
[5] GOOPTU M,KIM H T,JACOBSEN E,et al.Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis[J].Blood Adv,2023,7(11):2309-2316.
[6] DAS R,GUAN P,SPRAGUE L,et al.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis[J].Blood,2016,127(13):1666-1675.
[7] LIU P P,PAN X Y,CHEN C,et al.Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J].Blood,2020,135(11):826-833.
[8] 中国医师协会血液科医师分会,中华医学会儿科学分会血液学组,噬血细胞综合征中国专家联盟.中国噬血细胞综合征诊断与治疗指南(2022年版)[J].中华医学杂志,2022,102(20):1492-1499.
[9] LAI W Y,WANG Y N,WANG J S,et al.L-DEP is an effective treatment for adult and adolescent patients with epstein-barr virus-associated hemophagocytic lymphohistiocytosis[J].Blood,2016,128(22):2521.
[10] XU L Y,GUO X F,GUAN H Z.Serious consequences of Epstein-Barr virus infection:Hemophagocytic lymphohistocytosis[J].Int J Lab Hematol,2022,44(1):74-81.
[11] 吴梦慧,徐晓军.JAK1/2抑制剂芦可替尼治疗噬血细胞综合征的研究进展[J].医学研究杂志,2021,50(11):142-146.
[12] AHMED A,MERRILL S A,ALSAWAH F,et al.Ruxoliti
nib in adult patients with secondary haemophagocytic lymphohistiocytosis:an open-label,single-centre,pilot trial[J].Lancet Haematol,2019,6(12):e630-e637.
[13] ZHANG Q,ZHAO Y Z,MA H H,et al.A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis[J].Blood,2022,139(24):3493-3504.
[14] WANG J S,ZHANG R,WU X Y,et al.Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis:a single-arm,multicentre,phase 2 trial[J].Br J Haematol,2021,193(4):761-768.
[15] WANG J,GE J S,WANG Y A,et al.EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1[J].Nat Commun,2022,13(1):866.
[16] 王旖旎,高卓,张嘉,等.CD8+T细胞功能耗竭与继发性噬血细胞综合征发病的关系及其机制研究[J].中国实验血液学杂志,2021,29(3):963-968.
[17] PI Y B,WANG J S,WANG Z.Successful treatment of relapsed epstein-barr virus-associated hemophagocytic lymphohistiocytosis after allo-HSCT with PD-1 blockade:a case report[J].Infect Drug Resist,2022,15:3751-3756.
[18] QIU M Z,HE C Y,LU S X,et al.Prospective observation:clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients[J].Int J Cancer,2020,146(1):272-280.
[19] GAO Z,WANG Y N,WANG J S,et al.The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis[J].Clin Immunol,2019,202:18-28.
[20] 中华医学会儿科学分会感染学组,全国儿童EB病毒感染协作组.儿童EB病毒感染相关疾病的诊断和治疗原则专家共识[J].中华儿科杂志,2021,59(11):905-911. |
